Literature DB >> 27681493

New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review.

Simone Albisinni1, Fouad Aoun2, Thierry Roumeguère2, Francesco Porpiglia3, Andrea Tubaro4, Cosimo DE Nunzio4.   

Abstract

INTRODUCTION: Life expectancy is constantly increasing and as a consequence older men, frequently with multiple comorbidities, are seeking treatment for benign prostatic hyperplasia. Given their frail health, these men need extreme attention in their management, as efficacious and safe treatment strategies in the general population may not be adequate for them. EVIDENCE ACQUISITION: The National Library of Medicine Database was searched for relevant articles published between 2006 and 2015. Each article's title, abstract and text were reviewed for their appropriateness and their relevance. 57 articles were eligible for the review. EVIDENCE SYNTHESIS: In the elderly and frail, α1-antagonists should be used with caution given the risk of orthostatic hypotension and consequent falls, cause of significant morbidity in the elderly. 5ARIs present a good safety profile. Anticholinergics must also be prescribed with caution, given the risk of aggravating symptoms of dementia due to a central blockage of cholinergic neuronal pathways. Prostatic urethral lift is a medical device with low morbidity and valid functional results, which appear to endure over time. Prostatic artery embolization is demonstrating good results with minimal complication rates. Laser prostate vaporization or enucleation is also safe in elderly men and in those receiving anticoagulation therapy, due to its excellent hemostatic effect on prostatic tissue.
CONCLUSIONS: Urologists should be familiar with the safety and efficacy profile of medical and surgical therapy in the elderly population, given the inevitable increase in older patients which we will observe in the near future.

Entities:  

Mesh:

Year:  2016        PMID: 27681493     DOI: 10.23736/S0393-2249.16.02743-0

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  4 in total

1.  Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases.

Authors:  Paola Irene Ornaghi; Angelo Porreca; Marco Sandri; Alessandro Sciarra; Mario Falsaperla; Giuseppe Mario Ludovico; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-07-22       Impact factor: 5.455

Review 2.  The Efficacy and Safety of Laser and Electrosurgical Transurethral Procedures for the Treatment of BPO in High-Risk Patients: A Systematic Review.

Authors:  Glyn Burtt; Cassandra Springate; Alison Martin; Emily Woodward; Paul Zantek; Feras Al Jaafari; Gordon Muir; Vincent Misrai
Journal:  Res Rep Urol       Date:  2022-06-17

3.  Ejaculation-sparing thulium laser enucleation of the prostate (ES-ThuLEP): outcomes on a large cohort.

Authors:  Giorgio Bozzini; Lorenzo Berti; Matteo Maltagliati; Umberto Besana; Alberto Calori; Alexander Müller; Maria Chiara Sighinolfi; Salvatore Micali; Antonio Luigi Pastore; Rodrigo Ledezma; Paolo Broggini; Bernardo Rocco; Carlo Buizza
Journal:  World J Urol       Date:  2020-09-14       Impact factor: 4.226

4.  Prostatic artery embolization in people with spinal cord injury: a safe and effective technique to ease intermittent catheterization in case of concomitant benign prostatic hyperplasia.

Authors:  Gianluca Sampogna; Fabiane Barbosa; Pietro Maria Brambillasca; Emanuele Montanari; Antonio Rampoldi; Michele Spinelli
Journal:  Spinal Cord Ser Cases       Date:  2022-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.